AUROPHARMA

Aurobindo Pharma announced its Q4 FY26 results on 21 May 2026,

Aurobindo Pharma announced its Q4 FY26 results on 21 May 2026, reporting steady growth with revenue up 5.6 % YoY to ₹8,853 crore and net profit up 2 % to ₹921 crore. EBITDA stood at ₹1,801 crore with a 20.3 % margin, driven by strong European and API business performance. Metric Q4 FY26 Q4 FY25 Change YoY Revenue from Operations ₹8,853 crore ₹8,382 crore +5.6 % EBITDA ₹1,801 crore ₹1,792 crore + 0.5 % EBITDA Margin 20.3 % 21.4 % –104 bps Net Profit ₹921 crore ₹903 crore +2.0 % PBT (before JV share) ₹1,293 crore ₹1,367 crore –5.4 % R&D Spend ₹400 crore (4.5 % of revenue) — — Segment & Geographic Performance Europe Business: Revenue ₹2,795 crore (↑ 30.2 % YoY); crossed €1 billion annual mark. US Formulations: US $ 387 million (≈ 40 % of total revenue); 12 new product launches and 9 ANDA approvals. API Division: Revenue ₹1,208 crore (↑ 12.9 % YoY); growth driven by non‑antibiotic segment. ARV Portfolio: Revenue ₹328 crore (↑ 6.4 % YoY). Growth Markets: Revenue ₹980 crore (↑ 24.7 % YoY). Management Commentary Chairman P.V. Ramakrishna Reddy highlighted that Aurobindo’s European and API segments were key growth drivers amid stable US operations. The company maintains a strong cash position post acquisition of Khandelwal Laboratories (non‑oncology business). Focus for FY27: accelerate biosimilars commercialization and expand manufacturing capacity in Hyderabad and Vizag.